FDA Grants RMAT Designation to CAR T Therapy Obe-Cel for Lupus and Lupus Nephritis

The FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to obecabtagene autoleucel (obe-cel), Autolus Therapeutics’ CAR T cell therapy, for the treatment of systemic lupus erythematosus (SLE) and lupus nephritis (LN). The designation, announced September 9, 2026, is based on Phase 1b data showing high rates of disease remission in patients with severe, treatment-resistant disease.

Table of Contents

• What Happened
• From Blood Cancer to Autoimmune Disease
• What the Phase 1 Data Show
• What Comes Next
• Why This Matters
• Conclusion

What Happened

Autolus Therapeutics announced on September 9, 2026, that the FDA granted RMAT designation to obe-cel for systemic lupus erythematosus and lupus nephritis, based on Phase 1b data from the ongoing CARLYSLE trial. RMAT designation, created under the 21st Century Cures Act, is intended to accelerate development and regulatory review of regenerative medicine therapies, including cell therapies, for serious or life-threatening diseases, offering sponsors more frequent FDA interaction and potential eligibility for accelerated approval pathways.

From Blood Cancer to Autoimmune Disease

Obe-cel is a CD19-targeting autologous CAR T-cell therapy distinguished by a “fast off-rate” binding domain, designed to reduce the toxicity typically associated with CAR T treatment. It’s already an approved, commercially launched therapy: marketed as Aucatzyl, obe-cel received FDA, EMA, and MHRA approval for adult relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) and launched commercially in the US and UK in 2025. The RMAT designation marks Autolus’s push to extend the same CD19-targeting mechanism, which depletes B cells, into autoimmune disease, where errant B cells are believed to drive conditions like lupus.

What the Phase 1 Data Show

The CARLYSLE trial is an ongoing Phase 1 study evaluating obe-cel in patients with severe, refractory SLE who had exhausted other treatment options. Updated data presented at the American Society of Hematology Annual Meeting in December 2025 showed that among six patients treated at the selected 50-million-cell dose, five of six (83%) achieved remission according to the Definition of Remission in SLE (DORIS) criteria, and half achieved a complete renal response. All patients in the trial had refractory lupus nephritis, and four of six had significantly impaired kidney function at baseline. Responses and remissions were ongoing at a median follow-up of 8.9 months, with no dose-limiting toxicities, no immune effector cell-associated neurotoxicity syndrome (ICANS), and no high-grade cytokine release syndrome reported. Steroids were tapered to low maintenance doses in all patients by month six.

What Comes Next

Autolus has aligned with the FDA on the design of LUMINA, a pivotal Phase 2 trial in lupus nephritis with registrational intent, which is currently enrolling patients across five countries. The company expects to report data from LUMINA in 2028. A further Phase 1 CARLYSLE data update has been submitted for presentation at the American College of Rheumatology Annual Meeting in the fourth quarter of 2026.

Why This Matters

Systemic lupus erythematosus and lupus nephritis remain difficult to treat once patients become refractory to standard immunosuppressive therapy, and current options rarely produce durable, drug-free remission. The CARLYSLE data’s most notable signal is a “deep reset” of the B-cell compartment following a single CAR T infusion, raising the possibility that a one-time cellular therapy could induce lasting remission rather than requiring chronic immunosuppression. For the regenerative medicine field, obe-cel’s expansion from an approved oncology product into autoimmune disease is also a notable proof point for CAR T platforms more broadly: several other CD19-targeting cell therapies are now being tested in autoimmune indications following similar early signals of deep B-cell depletion and drug-free remission.

Conclusion

RMAT designation gives Autolus a more direct regulatory pathway as it moves obe-cel into pivotal testing for lupus nephritis, but with LUMINA data not expected until 2028, this remains an early-stage program. The scale of the CARLYSLE remission data, however, makes this one of the more closely watched CAR T programs moving into autoimmune disease.

Sources

• GlobeNewswire / Autolus Therapeutics, “Autolus Therapeutics Announces FDA RMAT Designation Granted to Obe-cel for the Treatment of Systemic Lupus Erythematosus and Lupus Nephritis” — Read here
• Autolus Therapeutics, “Autolus Therapeutics Presents Updated Clinical Data from the CARLYSLE Trial … at ASH Annual Meeting 2025” — Read here
• StockTitan, “Autolus Gets FDA RMAT Designation for Obe-cel in Lupus” — Read here